The E3 ubiquitin ligase Trim13 regulates Nur77 stability via casein kinase 2α

Bin Huang1, Han Zhong Pei1, Hyeun-Wook Chang2 & Suk-Hwan Baek1

Nur77 is a member of the NR4A subfamily of nuclear receptors and has been shown to regulate various biological processes such as apoptosis and inflammation. Here, we show that Nur77 ubiquitination is mediated by the tripartite motif 13 (Trim13), a RING-type E3 ubiquitin ligase. The interaction between Nur77 and Trim13 was confirmed by co-immunoprecipitation. Moreover, we found that Lys539 in Nur77 ubiquitination is targeted for Trim13, which leads to Nur77 degradation. The Trim13-mediated ubiquitination of Nur77 was optimal in the presence of the E2 enzyme UbcH5. Importantly, in addition to Trim13-mediated ubiquitination, the stability of Nur77 was also regulated by casein kinase 2α (CK2α). Pharmacological inhibition of CK2 markedly increased Nur77 levels, whereas overexpression of CK2α, but not its inactive mutant, dramatically decreased Nur77 levels by promoting Nur77 ubiquitination. CK2α phosphorylated Ser154 in Nur77 and thereby regulated Nur77 protein levels by promoting its ubiquitin-mediated degradation. Importantly, we also show that degradation of Nur77 is involved in TNFα-mediated IL-6 production via CK2α and Trim13. Taken together, these results suggest that the sequential phosphorylation and ubiquitination of Nur77 controls its degradation, and provide a therapeutic approach for regulating Nur77 activity through the CK2α-Trim13 axis as a mechanism to control the inflammatory response.

Nur77, also known as NGF1B (nerve growth factor 1B), TR3, or NR4A1 (nuclear receptor subfamily 4 group member 1), was the first member of the NR4A family to be identified as a gene induced by NGF in PC12 cells1. Nur77 is an immediate early response gene and plays a variety role in response to diverse stimuli including cytokines, stress, and apoptotic signals2–4. Nur77 has been implicated in many pathological conditions, including cancer, immune disorders, and metabolic or neurological diseases5. It has been reported to have a regulation of inflammatory responses. For example, in vitro studies showed a rapid induction of Nur77 expression by lipopolysaccharide (LPS) in macrophages6, and overexpression of Nur77 resulted in attenuation of cytokines and chemokines7,8. In vivo, Nur77 knock-out mice are more susceptible to diseases including sepsis9, atherosclerosis10, airway inflammatory disease7. However, unlike other nuclear receptors whose functions are modulated by their ligands, endogenous ligands for Nur77 have not yet been identified. Therefore, regulation of Nur77 levels has been the primary focus for understanding its function. It has been reported that Nur77 levels are regulated by both transcriptional and post-transcriptional mechanisms11,12. In addition, post-translational modifications have also been described as being an important mechanism for the regulation of Nur77 levels. Among post-translational modifications, phosphorylation is the most common mechanism that has been shown to regulate Nur77 levels13–15. Interestingly, it is suggested that ubiquitination is also a possible mechanism for regulating Nur77 level16.

Protein degradation is one of the most important mechanisms for regulating protein levels, particularly for proteins with fast turnover. The reported half-life for Nur77 is extremely short, being of the order of 20–40 min16. Protein degradation mediated by ubiquitination is an important process that controls every aspect of cellular function. After sequential activation of ubiquitin by E1 and E2, E3 ligases transfer ubiquitin to internal lysine residues on target substrates to form mono ubiquitination or poly-ubiquitin. The specificity of ubiquitin transfer is conferred by ~ 600 E3 ligases in human cells. E3 ligases are classified based on the homologous to the E6AP carboxyl terminus (HECT), really interesting new gene (RING), or ring between ring fingers (RBR) domains. Studies on the interaction of Nur77 and ubiquitination have been previously reported by Hu et al. Celastrol promotes Nur77 ubiquitination at lysine 539 site by the mechanism of K63-linked chain formation by TNF receptor

1Department of Biochemistry & Molecular Biology, College of Medicine, Yeungnam University, Daegu, South Korea.
2College of Pharmacy, Yeungnam University, Gyeongsan, South Korea. Correspondence and requests for materials should be addressed to H.-W.C. (email: hwchang@yu.ac.kr) or S.-H.B. (email: sbaek@med.yu.ac.kr)
associated proteins that are rapidly degraded. We first examined the expression of Nur77 in nine cell lines using commercial antibodies. Among them, HeLa and A549 cell lines were found to highly express Nur77 compared to the other cell lines examined. However, the predicted Nur77 protein was represented by several bands, therefore we confirmed that these bands are Nur77 proteins by siRNA method (data not shown). We next determined whether Nur77 is degraded in two cell lines. Treatment of HeLa and A549 cell lines with the proteasome inhibitor MG132 led to an increased level of Nur77 (Fig. 1a). Based on these data, we hypothesized that Nur77 undergoes ubiquitin-mediated degradation in these cells. To test whether Nur77 does indeed undergo ubiquitination, we performed ubiquitination assay in HeLa cells. Immunoprecipitation (IP) of Nur77 followed by western blot analysis detected a ladder of HA-tagged Nur77 in the presence of MG132 (Fig. 1b). Because Nur77 ubiquitination signal was very weak, we confirmed Nur77 stability and ubiquitination in the overexpressed HeLa cells. Treatment with MG132 also increased Nur77 levels in the Flag-Nur77 or Myc-Nur77 overexpressed cells (Fig. 1c). We observed that Nur77 ubiquitination also clearly increased in a dose-dependent manner (Fig. 1d). Moreover, we examined Nur77 stability by cycloheximide (CHX) chase experiment. Treatment with CHX reduced levels of the Nur77 protein in a time-dependent manner. However, pretreatment with MG132 blocked this degradation of Nur77 (Fig. 1e). Taken together, we conclude that regulation of Nur77 turnover involves the ubiquitin-proteasome pathway.

**Results**

**Nur77 is degraded by the ubiquitin-proteasome pathway.** Nur77 is an orphan nuclear receptor that contains a predicted PEST sequence located at acidic amino acid residues 32–104. PEST sequences are associated with proteins that are rapidly degraded. We first examined the expression of Nur77 in nine cell lines using commercial antibodies. Among them, HeLa and A549 cell lines were found to highly express Nur77 compared to the other cell lines examined. However, the predicted Nur77 protein was represented by several bands, therefore we confirmed that these bands are Nur77 proteins by siRNA method (data not shown). We next determined whether Nur77 is degraded in two cell lines. Treatment of HeLa and A549 cell lines with the proteasome inhibitor MG132 led to an increased level of Nur77 (Fig. 1a). Based on these data, we hypothesized that Nur77 undergoes ubiquitin-mediated degradation in these cells. To test whether Nur77 does indeed undergo ubiquitination, we performed ubiquitination assay in HeLa cells. Immunoprecipitation (IP) of Nur77 followed by western blot analysis detected a ladder of HA-tagged Nur77 in the presence of MG132 (Fig. 1b). Because Nur77 ubiquitination signal was very weak, we confirmed Nur77 stability and ubiquitination in the overexpressed HeLa cells. Treatment with MG132 also increased Nur77 levels in the Flag-Nur77 or Myc-Nur77 overexpressed cells (Fig. 1c). We observed that Nur77 ubiquitination also clearly increased in a dose-dependent manner (Fig. 1d). Moreover, we examined Nur77 stability by cycloheximide (CHX) chase experiment. Treatment with CHX reduced levels of the Nur77 protein in a time-dependent manner. However, pretreatment with MG132 blocked this degradation of Nur77 (Fig. 1e). Taken together, we conclude that regulation of Nur77 turnover involves the ubiquitin-proteasome pathway.

**Trim13 is the E3 ligase required for Nur77 ubiquitination.** To identify the specific E3 ligase for Nur77 ubiquitination, we performed a comparative proteomics study in 293FT cells. The data in Fig. 2a show representative silver-stained images using vector or Flag-Nur77 overexpressed samples. By comparing these two lanes, ~10 bands were found to have different levels of expression, eight of which were successfully identified by LC-MS/MS analyses. The characteristics of the identified bands, including protein name, gene name, NCBI accession number, molecular mass, and protein score are summarized in Table 1. Among these identified proteins, two were related to ubiquitin E3 ligases; one was Trim13 and the other was Trim21. We cloned Trim13 or Trim21 into a Myc expression plasmid and assessed Nur77 stability. Overexpression of Trim13 strongly decreased Nur77 stability, whereas Trim21 did not affect Nur77 stability. We also tested the effect of Trim19, but it rather increased Nur77 stability (Fig. 2b). On the other hand, Trim13 knock-down by siRNA increased Nur77 stability and decreased their ubiquitination (Fig. 2c,d). The activity of Trim13 depends on the Cys10 and Cys13 (C10/13) residues which are active sites. Therefore, we constructed a double point mutant whereby the C10/13 residues were converted to A10/13 by site-directed mutagenesis and compared the stability of this Nur77 mutant with that of WT Trim13. Overexpression of WT Trim13 decreased Nur77 level, whereas C10/13A mutant partially recovered Nur77 stability (Fig. 2e). In addition, we observed that WT Trim13 increases Nur77 ubiquitination, on the other hand the C10/13A mutant was not (Fig. 2f). These results suggest that Trim13 activity mediates Nur77 ubiquitination, leading to its degradation. Next, we observed the interaction between Nur77 and Trim13 by immunoprecipitation. (Fig. 2g,h). Taken together, these data suggest that Trim13 is an important E3 ligase for Nur77 ubiquitination.

We analyzed the type of ubiquitin chain formed on Nur77 as a result of Trim13 activity. For this, we used a set of ubiquitin mutants in which all except one Lys residue was replaced by Arg. The ubiquitination of Nur77 itself was expected to have various chain formation including K27 and K63. The ubiquitination of Nur77 by Trim13 was most prominent in K48-linked chain formation (Fig. 3a). We used another ubiquitin mutants in which one Lys residue was replaced by Arg. Further experiment showed that the ubiquitination of Nur77 by Trim13 is dependent on K48-linked chain formation (Fig. 3b). However, the Nur77 ubiquitination by Trim13 was not associated with K63-linked chain formation (Fig. 3a,c).
Lys539 site is responsible for ubiquitination of Nur77 by Trim13. To find the specific site in the Nur77 ubiquitination, we generated a series of domain-containing mutants. As a references, the structure of Nur77 is presented in Fig. 4a (upper panel). Transfection with the putative ligand-binding domain (LBD) resulted in an ubiquitination of Nur77, whereas transactivation domain (TAD) did not change the ladder formation. DNA-binding domain (DBD) resulted in a slight increase ubiquitination that was clearly less than that seen with WT Nur77 (Fig. 4a). These data suggest that the site of Nur77 ubiquitination lies in the LBD. To identify precisely the site ubiquitinated by Trim13, we analyzed the protein sequence of Nur77 and found several lysine sites predicted to be likely ubiquitination sites. Most of the putative sites are located in the putative LBD, but some are located in the TAD. Based on the above, we generated five Nur77 mutants with an arginine (R) in place of each lysine (K) to identify target site. We then performed a CHX chase experiment to examine the effects of the mutants. Mutation of four sites (K422/426 R is double mutant) did not change Nur77 stability, whereas K539R did affect its stability (Fig. 4b). In addition, K539R mutant decreased the ubiquitination of Nur77 (Fig. 4c). Based on these data the K539 residue appears to be a specific site for Nur77 ubiquitination. This Lys site was consistent with the results of Hu et al. Next, we tested the role of K539 in the Trim13-mediated Nur77 stability. The K539R mutant significantly blocked degradation and ubiquitination of Nur77 by Trim13 (Fig. 4d,e). These data suggest that the K539 is important site for Trim13-mediated Nur77 ubiquitination.
An in vitro ubiquitination assay was performed to determine which E2 was involved in the Nur77 ubiquitination by Trim13. First, we obtained recombinant Trim13 protein from 293FT cells. A mixture containing recombinant Nur77, Flag-Trim13, E1 and different E2 enzymes was then incubated with ubiquitin in the absence or presence of Mg/ATP. Ubiquitination of Nur77 itself was increased by the UBE2S. However, Nur77 ubiquitination by Trim13 was optimal with UbcH5 among the E2 species tested; there was no difference between UbcH5 isoforms (Fig. 5). These data suggest that the E2 UbcH5 is involved in Trim13-mediated Nur77 ubiquitination.

CK2α is responsible for degradation of Nur77. Nur77 is a phosphoprotein that contains various putative phosphorylation sites for kinases such as c-jun N-terminal kinase, mitogen-activated protein kinase 1 (MAPK1), CK2, protein kinase A, and Akt15,21,26,28,29. To address the potential role of CK2 in Nur77 degradation, cells were treated with TBB (4,5,6,7-tetrabromobenzotriazole) or CX-4945 (Silmitasertib), specific inhibitors of CK2. Treatment with TBB or CX-4945 increased Nur77 protein levels (Fig. 6a). To confirm whether CK2 participates in Nur77 stability, WT CK2α and its mutant (K68M in the CK2α subunit, a kinase-dead form) were overexpressed in HeLa cells. Nur77 level was decreased in the cells overexpressing WT CK2α. However, its level was partially recovered in the cells overexpressing the K68M mutant (Fig. 6b). Furthermore, WT CK2α increased Nur77 ubiquitination, but had a lesser effect on the K68M mutant (Fig. 6c,d). Next, we tested the interaction between Nur77 and CK2α using immunoprecipitation with anti-Flag bead (Nur77) or anti-Myc antibody.
The data showed that CK2α interacts with Nur77 (Fig. 6e,f). These data suggest that CK2α interacts with Nur77 and regulates its ubiquitination.

The Ser154 residue in Nur77 is a target site for CK2α. A motif scan analysis revealed the presence of the putative CK2 target sites in the N-terminal of Nur77. Moreover, a computer alignment indicated that there were multiple sites within the 129–157 region of Nur77 that contained the potential optimal CK2 substrate motif (S-x-x-E/D/S/T) (Fig. 7a). To identify the exact CK2α target site, we generated point mutants at five serine residues (S129, S136, S139, S142 and S154) within the 129–157 region of Nur77 and performed a CHX chase assay. Of the five mutants, the S154A mutant most strongly affected the stability of Nur77. On the other hand, S129A, S139A and S142A mutants were not affected and the S136A mutant was less effective than the S154A mutant (Fig. 7b). To confirm that S154 residue is important for the ubiquitination of Nur77, the WT Nur77 or S154A mutant were transfected into cells. The mutant exhibited reduced ubiquitination compared with that of WT Nur77 (Fig. 7c). To prove that S154 residue of Nur77 is directly phosphorylated by CK2α, we made an antibody that is specific for Nur77 phosphorylated at S154. Although the S154 phosphorylation of Nur77 appeared in the vector-transfected cells, the transfection of CK2α increased these phosphorylation but the K68M mutant did not (Fig. 7d). CK2α knock-down by siRNA reduced the phosphorylation of S154 in Nur77 (Fig. 7e). These results imply that CK2α directly phosphorylates S154 of Nur77. Next, we confirmed the importance of S154 residue in CK2α-mediated Nur77 ubiquitination and stability. The expression of the S154A mutant partially blocked not

| Identified band No. | Protein name | Gene name | NCBI accession number | Molecular weight (Da) | Score |
|---------------------|--------------|-----------|-----------------------|-----------------------|-------|
| 1                   | CAD protein  | CAD       | NM_001306079.1        | 245317                | 36    |
| 2                   | Nuclear receptor subfamily 4 group A member 1 | NR4A1 | NM_001202233.1 | 65596 | 222  |
| 3                   | Nuclear receptor subfamily 4 group A member 2 | NR4A2 | NM_006177.1 | 67636 | 117  |
| 4                   | Heat shock protein HSP 90-beta | HSP90AB1 | NP_001258898.1 | 83602 | 84   |
| 5                   | Oxidative stress-induced growth inhibitor 2 | OSGIN2 | NP_001119583.1 | 57180 | 25   |
| 6                   | Mitochondrial inner membrane protein | IMM1 | NP_001109639.1 | 84094 | 23   |
| 7                   | Coiled-coil domain-containing protein 87 | CCDC87 | NP_006689.2 | 96805 | 21   |
| 8                   | Nuclear receptor subfamily 4 group A member 1 | NR4A1 | NM_001202233.1 | 65596 | 174  |
| 9                   | ATP-dependent RNA helicase DDX3X | DDX3X | NM_001193416.2 | 73640 | 66   |
| 10                  | ATP-binding cassette sub-family F member 2 | ABCF2 | NP_005692.4 | 71862 | 32   |
| 11                  | Eukaryotic translation initiation factor 4B | EIF4B | NM_001330654.1 | 69205 | 32   |
| 12                  | Melanoma-associated antigen D2 | MAGED2 | NP_014599.5 | 65125 | 27   |
| 13                  | Heat shock 70kDa protein 1A/1B | HSPA1A | AQY76873.1 | 70350 | 283  |
| 14                  | Probable ATP-dependent RNA helicase DDX5 | DDX5 | NM_001320595.1 | 69680 | 37   |
| 15                  | Protein arginine N-methyltransferase 5 | PRMT5 | NM_001039619.2 | 73378 | 29   |
| 16                  | RNA-binding protein 39 | RBBM39 | NP_001242599.1 | 59665 | 25   |
| 17                  | Rho GTPase-activating protein 25 | ARHGAP25 | NM_001007231.2 | 73964 | 22   |
| 18                  | Calcium-binding mitochondrial carrier protein Aralar2 | SLC25A13 | NM_001160210.1 | 74575 | 21   |
| 19                  | Inositol-triphosphate 3-kinase C | ITPKC | NP_025194.2 | 75950 | 19   |
| 20                  | Elongation factor 1-alpha 1 | EEFI1A | NP_001402.5 | 50477 | 49   |
| 21                  | E3 ubiquitin-protein ligase TRIM13 | TRIM13 | NM_001007278.2 | 46988 | 30   |
| 22                  | 60S ribosomal protein L4 | RPL4 | NM_000968.3 | 47984 | 22   |
| 23                  | Monoacylglycerol lipase ABHD12 | ABHD12 | NM_001042472.2 | 45545 | 21   |
| 24                  | E3 ubiquitin-protein ligase TRIM21 | TRIM21 | NP_003141.3 | 55207 | 18   |
| 25                  | Methylosome protein 50 | WDR77 | NP_001317062.1 | 36533 | 129  |
| 26                  | Eukaryotic initiation factor 4A-1 | EIF4A1 | NP_001407.1 | 46393 | 93   |
| 27                  | 60S ribosomal protein L3 isomorf a | RPL3 | NP_000958.1 | 46392 | 57   |
| 28                  | Cytochrome b-c1 complex subunit 2, mitochondrial | UQCRCC2 | NP_003357.2 | 48631 | 43   |
| 29                  | Zinc finger protein 778 isoform X3 | ZNF778 | XP_016875051.5 | 45940 | 27   |
| 30                  | Basement membrane-specific heparan sulfate Proteoglycan core protein isomorf b precursor | HSPG2 | NP_005520.4 | 47979 | 22   |
| 31                  | ADP/ATP translocase 2 | SLC25A5 | NM_001152.4 | 33078 | 108  |
| 32                  | ADP/ATP translocase 1 | SLC25A4 | NM_001151.3 | 33291 | 85   |
| 33                  | BTB/POZ domain-containing protein KCTD5 | KCTD5 | NM_018992.3 | 26493 | 46   |
| 34                  | Mitochondrial dicarboxylate carrier | SLC25A10 | NM_001270888.1 | 31738 | 44   |
| 35                  | Vesicle-associated membrane protein-associated protein B/C | VAPB | NM_001195677.1 | 27457 | 27   |
| 36                  | Histone H1x | H1FX | NP_006026.3 | 22488 | 20   |

Table 1. List of the characteristics of the identified bands.

(CK2α). The data showed that CK2α interacts with Nur77 (Fig. 6e,f). These data suggest that CK2α interacts with Nur77 and regulates its ubiquitination.

The Ser154 residue in Nur77 is a target site for CK2α. A motif scan analysis revealed the presence of the putative CK2 target sites in the N-terminal of Nur77. Moreover, a computer alignment indicated that there were multiple sites within the 129–157 region of Nur77 that contained the potential optimal CK2 substrate motif (S-x-x-E/D/S/T) (Fig. 7a). To identify the exact CK2α target site, we generated point mutants at five serine residues (S129, S136, S139, S142 and S154) within the 129–157 region of Nur77 and performed a CHX chase assay. Of the five mutants, the S154A mutant most strongly affected the stability of Nur77. On the other hand, S129A, S139A and S142A mutants were not affected and the S136A mutant was less effective than the S154A mutant (Fig. 7b). To confirm that S154 residue is important for the ubiquitination of Nur77, the WT Nur77 or S154A mutant were transfected into cells. The mutant exhibited reduced ubiquitination compared with that of WT Nur77 (Fig. 7c). To prove that S154 residue of Nur77 is directly phosphorylated by CK2α, we made an antibody that is specific for Nur77 phosphorylated at S154. Although the S154 phosphorylation of Nur77 appeared in the vector-transfected cells, the transfection of CK2α increased these phosphorylation but the K68M mutant did not (Fig. 7d). CK2α knock-down by siRNA reduced the phosphorylation of S154 in Nur77 (Fig. 7e). These results imply that CK2α directly phosphorylates S154 of Nur77. Next, we confirmed the importance of S154 residue in CK2α-mediated Nur77 ubiquitination and stability. The expression of the S154A mutant partially blocked not
only the ubiquitination but also the degradation of Nur77 (Fig. 7f,g). These results suggest that S154 phosphorylation of Nur77 by CK2α regulates Nur77 ubiquitination and degradation.

**TNFα stimulates Nur77 degradation via CK2α-Trim13 pathway.** To determine the physiological significance of Nur77 degradation, we attempted to identify specific signal that mediate this phenomena and found TNFα. TNFα activity is a typical inflammation inducer in many cells. Indeed, TNFα treatment dramatically induced Nur77 protein as well as mRNA in HeLa cells, but these protein was rapidly degraded afterwards. However, pretreatment with MG132 sustained TNFα-induced Nur77 degradation (Fig. 8a). In addition, TNFα treatment increased the ubiquitination of Nur77 (Fig. 8b). These results suggest that the ubiquitin-proteasome pathway exists in TNFα-induced Nur77 regulation. Next we tested that effects of Trim13 and CK2α on Nur77 degradation mediated by TNFα. Overexpression of CK2α accelerated TNFα-induced Nur77 degradation (Fig. 8c). Similarly, TNFα-induced Nur77 proteins were degraded faster in Trim13-transfected cells than in vector-transfected cells (Fig. 8d). Taken together, these results suggest that both CK2α and Trim13 were involved in degradation of Nur77 mediated by TNFα. To examine the importance of S154 (phosphorylation site) and K539 (ubiquitination site) residues in TNFα-mediated Nur77 degradation, we compared stability in response to TNFα.
The degradation of Nur77 induced by TNFα was ablated in the S154A or K539R mutants (Fig. 8e,f) suggesting that both the S154 and K539 residues are important for TNFα-mediated Nur77 stability.

Nur77 suppresses TNFα-induced IL-6 production. One important role of Nur77 is to control inflammation. Recently, Nur77 has been reported to exhibit an anti-inflammatory activity19. We therefore investigated the role of Nur77 in the TNFα-induced IL-6 production. Overexpression of Nur77 inhibited TNFα-induced IL-6 production, whereas knock-down of Nur77 using a targeted siRNA further increased TNFα-induced IL-6 production (Fig. 9a,b). Treatment of the Nur77 inhibitor, ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)phenyl]acetate (TMPA) also further increased TNFα-induced IL-6 production (Fig. 9c). Next, we examined the relationship

Figure 4. K539 residue is important for Trim13-mediated Nur77 ubiquitination and degradation. (a) 293FT cells were transfected with either WT Nur77, or its domain mutants as indicated, and the lysates were analyzed by IP and IB as indicated. Ten percent of the input lysate was analyzed by IB with a Flag antibody. Schematic representation of Nur77 constructs used in this study (upper scheme). WT, wild type; TAD, transactivation domain; DBD, DNA-binding domain; LBD, ligand-binding domain. (b) Cells were transfected with WT Nur77 or its mutants and then treated with CHX for the indicated times, following which lysates were analyzed by IB. (c) Cells were transfected with either WT Nur77 or K539R to access ubiquitination and analyzed by IP and IB as indicated. (d) Cells were co-transfected with WT Nur77, or indicated mutants, in the absence or presence of Trim13. The protein levels of Nur77 and Trim13 were evaluated. Nur77 levels were quantified by densitometry and the values determined are shown under each corresponding band. (e) HeLa cells were co-transfected with WT Nur77, or its K539R mutant, in the absence or presence of Trim13 to access ubiquitination and analyzed by IP and IB as indicated.
between Nur77 and IL-6 production based on the effect of CK2α or Trim13 on TNFα treatment. Transfection of CK2α potentiated TNFα-stimulated IL-6 production compared to vector, whereas transfection of the K68M mutant did not (Fig. 9d). Trim13 showed similar effects to CK2α. In other words, transfection of Trim13 potentiated TNFα-stimulated IL-6 production, whereas transfection of the C10/13A mutant did not (Fig. 9e). Taken together, those data suggest that changes in Nur77 levels, effected by CK2α or Trim13, play a role in the production of IL-6 in response to TNFα.

**Discussion**

In the present study, using proteomic approach, we have shown that Nur77 is ubiquitinated by the E3 ligase Trim13 leading to its degradation, and furthermore have uncovered the regulatory pathway that controls this ubiquitination. The K539 residue in Nur77 was shown to be the site of ubiquitination mediated by the E3 ligase Trim13. In parallel, the protein kinase CK2α was shown to be able to phosphorylate Nur77. We demonstrated that phosphorylation of S154 by CK2α in Nur77 is important for its stability. Furthermore, physiologically, Nur77 is degraded by ubiquitination in response to TNFα stimulation. The possibility of regulating Nur77 stability through ubiquitination has been previously suggested, but not many studies has successfully identified the actual E3 ligase involved. Nur77 contains a putative PEST sequence located at its N-terminus, which is a potential proteolytic cleavage site. Our initial goal was to identify the E3 ligase that could stimulate Nur77 ubiquitination. Using a proteomics analysis both Trim13 and Trim21 were identified as potential E3 ligases capable of binding Nur77. Trim13 was able to modulate Nur77 stability in cells but Trim21 was not. As part of this study, we observed that Trim28, another Nur77 binding protein, as well as Trim19 and Trim21 was not able to decrease Nur77 stability (data not shown). Very recently the protein inhibitor of activated STAT3 (PIAS3) has been reported as being a SUMO E3 ligase that can promote SUMOylation and degrade Nur77. On the other hand,
Smad ubiquitination regulatory factor 1 (Smurf1) has been reported to be able to inhibit Nur77 degradation. Therefore, these reported data suggest that various kinds of E3 ligases are involved in Nur77 ubiquitination through different mechanisms.

Trim13, a member of the Trim family, has been reported to play a role in diverse cellular functions such as cell death, cancer, and immunity. Trim13 was firstly identified as a RING E3 ligase and plays a role in endoplasmic reticulum (ER)-associated degradation. Further studies have shown that Trim13 regulates autophagy caused by ER stress. To date, L-type channels, Akt, and caspase-8 have been shown to be substrates for Trim13-mediated ubiquitination. Nevertheless, the specific substrates for Trim13 are still not very well characterized. Trim13, along with Trim59, is a unique E3 ligase since it contains a transmembrane domain, and is known to target only a few substrates. The active sites of Trim13 contain two cysteine residues (Cys10 and Cys13) that are important for ubiquitination of substrate. In this study, we have conclusively demonstrated that the ubiquitination and degradation of Nur77 are dependent on this Trim13 ligase activity. Using domain deletion mutants, we were able to identify the Nur77 ubiquitination site as being in its putative LBD, and through further detailed point mutation analyses, we found K539 was the target lysine ubiquitinated by Trim13. As we mentioned results, this Lys site was consistent with the results of Hu et al. It should be noted, however, that the K539R mutant was not able to completely inhibit Nur77 ubiquitination, suggesting that more target sites exist within Nur77.

Nur77, along with Nur1 and Nor1, is an orphan nuclear receptor of the Nr4A family which has been recently studied as therapeutic target for inflammation. The Nur77 receptor is rapidly induced by various inflammatory stimuli, suggesting that it has an important role in the inflammatory response. However, the mechanism by which Nur77 functions is not clear, principally because its ligands remain to be discovered. The Nur77 receptor has a
bulky hydrophobic residue in place of the ligand-binding pocket that is usually found in other nuclear receptor LBDs. Thus, it is also believed Nur77 does not bind a ligand, but rather functions as a ligand-independent transcription factor. There have however been several reports where synthetic molecules can act both as agonists or antagonists through direct binding to the LBD, therefore it is still possible that a ligand exists. Regardless of the issue concerning its ligand, it appears that transcriptional regulation is the most well described function of Nur77. Post-translational modifications, such as phosphorylation have also been suggested to be important regulators of Nur77. Our study has convincingly shown that ubiquitination of Nur77 by an E3 ligase is also an important mechanism in regulating its activity. In addition, a very recent study has shown that SUMOylation may also be important in regulating Nur77. Therefore, it is important to identify these various regulatory mechanisms that control Nur77 stability in order to fully understand its physiological function.

The most important finding of this study is that the connection between phosphorylation and ubiquitination acts as an essential mechanism regulating Nur77 stability. Our results suggest that phosphorylation on a specific Nur77 serine residue promotes Nur77 ubiquitination, further decreasing its stability. The possibility of Nur77 being regulated by phosphorylation has been suggested previously, and many putative target sites capable of being phosphorylated by kinases have been described, including phosphorylation of S97 by JNK, T145/S434 by MAPK1, S166 by DNA-PK, S344 by PKA, S354 by either S6K or Akt, etc. However, the connection between a specific Nur77 kinase and a specific Nur77 E3 ligase has not been made. We mutagenized many potential phosphorylation sites and examined their effect on Nur77 stability. Uniquely, mutagenesis of S154 was able to affect Nur77 stability. Based on this, we believe phosphorylation of S154 is a crucial for regulating Nur77 stability. It should be pointed out that mutation of T145, which is known to be phosphorylated by MAPK1, also

---

**Figure 7.** S154 of Nur77 is a target for CK2α-mediated phosphorylation and stability. (a) Schematic representation of the Nur77 protein. Bold characters, putative CK2α-phosphorylation sites. (b) WT Nur77 or various point mutants were transfected into cells and treated with CHX for the indicated times. The protein levels of Nur77 were evaluated by IB. (c) HeLa cells were transfected with either WT Nur77, or the S154A mutant to access ubiquitination and were then analyzed by IP and IB as indicated. Ten percent of the input lysate was analyzed by IB. (d) Nur77 was co-transfected along with either WT CK2α or K68M mutant to access phosphorylation, and were then analyzed by IB using phospho-Nur77 (pSer154) or Nur77 (total Nur77) antibody. (e) HeLa cells were transfected with either control siRNA or CK2α siRNA to access Nur77 phosphorylation and analyzed by IB as indicated. (f) Cells were transfected with either WT Nur77, or the S154A mutant, in the absence or presence of CK2α to access ubiquitination and were analyzed by IP and IB as indicated. (g) HeLa cells were transfected with either WT Nur77, or the S154A mutant, in the absence or presence of CK2α to access stability and were analyzed by IB as indicated.
had a slight effect on Nur77 stability; therefore, we are currently studying the role of MAPK1 in regulating Nur77 stability.

A motif scan analysis indicated that T55, S129, and S154 are potential sites for CK2. However, there were five putative target serine residues that are located between residues 129 and 157. When each individual serine was mutated to alanine, the S154 mutation had the strongest effect on Nur77 stability. These data therefore suggest that S154 phosphorylation by CK2 is important in controlling Nur77 stability. The CK2α phosphorylation site that we have identified in Nur77 is highly conserved across species including human, mouse, rat, bovine, and dog. However, alignment of this site across the two other Nur77 isoforms, Nurr1 and Nor1, did not reveal a consensus sequence. This suggest that the ubiquitination mechanism differs depending on the Nr4A isoform. Currently, it is estimated that CK2 has over 300 substrates that it can phosphorylate, and included among those are IκB, p21, p53, β-catenin, and breast cancer type 2 susceptibility protein 1 (BRCA1), which are all known to be regulated by a degradation mechanism. Therefore, we believe Nur77 is also part of this group of CK2 substrate proteins that are regulated.

One of the most important functions of Nur77 is in the regulation of inflammation. Nur77 was initially identified as a pro-inflammatory factor, which was found to be abnormally overexpressed in inflamed synovial tissues, atherosclerosis, and multiple sclerosis. In addition, pro-inflammatory stimuli such as lipopolysaccharide were known to also induce the expression of Nur77. On the other hand, Nur77 acted as an anti-inflammatory in macrophages, epithelial cells, and endothelial cells, and therefore has been suggested to have anti-inflammatory actions. A lack of Nur77 has been shown to increase inflammation, and there have been reports showing that Nur77 protects against lipopolysaccharide-induced sepsis, also supporting the idea that Nur77 is an anti-inflammatory regulator. Our data shows that Nur77 overexpression inhibited TNFα-induced IL-6 production, whereas Nur77 knock-down increased IL-6 production. These results support that Nur77 could indeed act as an anti-inflammatory regulator. We believe that although TNFα increases Nur77 expression, and after a certain time Nur77 becomes degraded, decreasing the levels of this anti-inflammatory molecule, eventually causing elevated inflammation. Therefore, it is possible that the Nur77 level is important as an indicator of inflammation in cells. However, there is insufficient information on why TNFα drastically increases Nur77 expression. One hypothesis is that the expression of Nur77 is increased as part of defensive mechanism during the acute inflammatory response, but further mechanistic studies will be needed to fully understand this process.

Figure 8. TNFα stimulates Nur77 degradation by ubiquitin-proteasome pathway. (a) HeLa cells were treated with TNFα (5 ng/mL) for the indicated times, in the absence or presence of MG132 (10 μM). The protein levels of Nur77 were evaluated by IB. (b) HeLa cells were transfected with Nur77, and then treated with vehicle or TNFα for 4 h to access ubiquitination and analyzed by IP and IB as indicated. (c) HeLa cells were transfected with vector or CK2α, and then treated with TNFα for the indicated times. (d) HeLa cells were transfected with vector or Trim13, and then treated with TNFα for the indicated times. The protein levels of Nur77 were evaluated by IB. (e) HeLa cells were transfected with either WT Nur77, or the S154A mutant, and treated with vehicle or TNFα. (f) HeLa cells were transfected with either WT Nur77, or the K539R mutant and treated with vehicle or TNFα. The protein levels of Nur77 were evaluated by IB.
Materials and Methods

Plasmids. Full-length mouse Nur77 cDNA was cloned into the pFLAG-CMV2 vector. For Myc-tagged Nur77, Nur77 was amplified from pcMV2 Flag-tagged Nur77 by PCR and inserted into the EcoRI/BamHI sites. Full-length mouse Trim13 cDNA was also cloned into pFLAG-CMV2, pEGFP-C1, or pCMV2-Myc vectors. In order to construct Myc-tagged CK2α, CK2α was amplified from pRC/CMV-HA-CK2α by PCR and inserted into the EcoRI/BglII sites. Wild-type pRC/CMV-MA-CK2α and its mutant (K68M) were purchased from Addgene (Cambridge, MA). For Myc-tagged CK2α, CK2α was amplified from pRC/CMV HA-tagged CK2α by PCR and inserted into the EcoRI/BglII sites. Site-directed mutagenesis (C→A, S→A, or K→R) was performed using the Quick change mutagenesis kit and verified by performing DNA sequencing (Agilent branch, Daegu, South Korea). Recombinant Nur77 protein was purchased from Abcam (Cambridge, UK). Ubiquitin and all ubiquitin mutants were cloned into pCMV-HA-N vector (Clontech, Mountain View, CA).

Cell culture and RNA interference. U2OS, HeLa, and 293FT cells were cultured in RPMI medium supplemented with 10% fetal bovine serum (FBS). All cell cultures followed standard procedures. Cultured cells were transfected using Lipofectamine 3000 reagents for plasmid transfections and LipoRNAiMax (Invitrogen; Thermo Fisher Scientific, Carlsbad, CA) for siRNA transfections. Nur77 siRNA (5′-CAG CAU UAU GGU GUC CGC ACA UGU G-3′) and Trim13 siRNA (5′-UAA UGA AUG UGCCAG UGU CUU GAG G-3′) were purchased from Invitrogen (Thermo Fisher Scientific). CK2α siRNA (sc-29918) was purchased from Santa-Cruz biotechnology.

Antibodies and immunoblotting. The following antibodies were used in this study: a polyclonal anti-Nur77 antibody (Cell Signaling Technology, Beverly, MA or Proteintech, Rosemont, IL); an anti-Flag-M2 antibody (Sigma-Aldrich, St. Louis, MO); an anti-Myc antibody, an anti-HA antibody, and an anti-GFP antibody, anti-CK2α antibody (Santa Cruz Biotechnology, Dallas, TX); as well as the appropriate horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology). Cell extracts were prepared in NP-40 buffer (50 mM Tris-Cl (pH 8.0), 105 mM NaCl, 1% NP-40, 1% SDS, and protease inhibitor cocktail [Roche Diagnostics, Indianapolis, IN]). Proteins were resolved by performing SDS-PAGE and were transferred onto an Amersham Protran NC membrane (GE Healthcare Life science, Freiburg, Germany). Immunoblots were visualized using the LAS-3000 system (GE Healthcare Life science). Densitometric analysis was carried out using LAS-3000 Image Reader and MultiGauge 3.0 software.
Silver staining and LC-MS/MS. Protein separation was performed by 10% SDS-PAGE, the gels were fixed with 50% methanol/12% acetic acid containing 0.05% formalin at room temperature for 1 h, and washed with 35% ethanol. The gels were sensitized with 0.02% sodium thiosulfate for 2 min and then washed with water for 15 min. After incubation with 0.2% silver nitrate containing 0.076% formalin, the gels were developed in 6% sodium carbonate containing 0.004% sodium thiosulfate and 0.05% formalin. The development reaction was stopped in 50% methanol and 12% acetic acid. Significant bands were cut, digested, and analyzed by LC-MS/MS from ProteomTech Inc (Daejeon, South Korea). In this sample, peptide match scores above 17 were considered statically significant.

Generation of Nur77 phospho-specific antibody. Phospho-specific antibody against Ser154 site of Nur77 was generated in rabbits by Antibody Frontier (Seoul, South Korea) using the phospho-peptide QPSQL(pS)PWDGS. Antibodies against Ser154 site showed good responses and were affinity purified.

Ubiquitination assay. Cells were transfected with vectors expressing each gene as indicated. At 36 h after transfection, the cells were treated with the proteasome inhibitor MG132 (10 μM) for 5 h. Next, the cells were collected in PBS and 5%~10% of the cell suspension was stored as input. The remainder of the cell suspension was centrifuged for 5 min, and the cells were then lysed in 700 μl of ubiquitination buffer (0.5% Nonidet P-40, 50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 2 mM MgCl₂, 5 mM N-ethylmaleimide, and protease inhibitor cocktail). The lysates were then centrifuged at 12,000 × g for 10 min, and then incubated with 1.5% SDS and 1 mM dithiothreitol at 65 °C for 20 min in order to denature the proteins, after which they were diluted 10-fold with lysis buffer. The denatured lysates were incubated overnight with the indicated antibodies and protein A/G PLUS agarose (Santa Cruz Biotechnology, Dallas, TX), resolved by SDS-PAGE, and immunoblotted with the indicated antibodies. For in vitro ubiquitination assay, recombinant Nur77 protein was purchased from Abcam (Cambridge, UK). Recombinant Trim13 protein was obtained from Flag-tagged Trim13 expressing HeLa cells and purified using anti-Flag-M2 affinity gel (Sigma-Aldrich, St. Louis, MO). The in vitro ubiquitination assay of Nur77 was performed using VIVAlink ubiquitin kit (VIVA bioscience, Exeter, UK). The reaction mixtures (ubiquitin assay buffer, 1 μM E1, 25 μM E2, 100 μM ubiquitin, 50 mM Mg-ATP, 100 ng recombinant Nur77 and Trim13 protein) were incubated at 37 °C for 2 h. Ubiquitinated Nur77 was detected by western blotting using an ubiquitin antibody.

Protein half-life analysis. A cycloheximide (CHX) blocking analysis was performed to determine the half-life of Nur77. Cells were incubated with CHX (50 μg/ml) for various times, and Nur77 was detected by western blot analysis. The density of the immunoreactive bands corresponding to Nur77 and β-actin were measured. The level of Nur77 was quantified by normalization with β-actin, and the percentage of remaining Nur77 was plotted.

Quantification of IL-6 production by EIA. The cell culture supernatants were collected at various time points treated or untreated with the indicated ligand or inhibitors. The protein standards and antibody pairs for IL-6 were procured from R&D systems (Minneapolis, MN). EIA experiment for IL-6 measurement was performed according to the manufacturer's instructions.

Co-immunoprecipitation. For the co-immunoprecipitation assay, cells grown in 10 cm dishes were transfected with various plasmids, and lysates were prepared 36 h after transfection. Cells were lysed in RIPA buffer (20 mM HEPES [pH 7.5], 1% NP-40, 0.1% SDS, 0.5% deoxycholic acid, and 150 mM NaCl) containing 10 μM NaF and protease inhibitor cocktail. Cell lysates were incubated with the appropriate antibody for overnight and subsequently incubated with protein A-Sepharose beads for 1 h. The protein-antibody complexes recovered on beads were subjected to western blotting using appropriate antibodies after separation by SDS-PAGE.

Purification of Trim13 recombinant protein. HeLa cells were grown in 10 cm dishes and were transfected with Flag vector or Flag-Trim13 plasmids (each ten dishes). After 36 h, the cells were washed two times in ice-cold PBS, and lysed in cell lysis buffer containing protease inhibitors. Flag-Trim13 lysate was incubated with Flag beads overnight. The beads were extensively washed with the lysis buffer containing protease inhibitors. The protein bound to beads was eluted with the Flag peptide and the beads were centrifuged and the supernatant containing Trim13 proteins were stored at −80 °C before CBB staining and in vitro ubiquitination assays were performed.

Statistical analysis. Optical intensity was measured using the AlphaEase program (Version 5.1: Alpha Innotech, San Leandro, CA). Data were analyzed using GraphPad Prism Version 4 (GraphPad Software Inc., San Diego, CA). All numerical values are presented as mean ± SD. Statistical significance was determined using an unpaired Student’s t-test.

References
1. Milbrandt, J. Nerve growth factor induces a gene homologous to the glucocorticoid receptor gene. Neuron 1, 183–188 (1988).
2. Bonta, P. I. et al. Nuclear receptors Nur77, Nurr1, and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses. Arterioscler Thromb Vasc Biol 26, 2288–2294, https://doi.org/10.1161/01.ATV.000038346.84458.5d (2006).
3. Martinez-Gonzalez, J. & Badimon, L. The NR4A subfamily of nuclear receptors: new early genes regulated by growth factors in vascular cells. Cardiovasc Res 65, 609–618, https://doi.org/10.1016/j.cardiores.2004.10.002 (2005).
4. Zhou, Y. et al. Induction of Nur77-dependent apoptotic pathway by a coumarin derivative through activation of JNK and p38 MAPK. Carcinogenesis 35, 2660–2669, https://doi.org/10.1093/carcin/bgu186 (2014).
34. Lerner, M.
26. van Tiel, C. M., Kurakula, K., Koenis, D. S., van der Wal, E. & de Vries, C. J. Dual function of Pin1 in NR4A nuclear receptor
25. Scaglioni, P. P.
33. Rajsbaum, R., Garcia-Sastre, A. & Versteeg, G. A. TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral
37. Rodriguez-Calvo, R., Tajes, M. & Vazquez-Carrera, M. The NR4A subfamily of nuclear receptors: potential new therapeutic targets
38. Wansa, K. D., Harris, J. M. & Muscat, G. E. The activation function-1 domain of Nur77/NR4A1 mediates trans-activation, cell
39. Zhan, Y. Y.
11. Perez-Sieira, S., Lopez, M., Nogueiras, R. & Tovar, S. Regulation of NR4A by nutritional status, gender, postnatal development and hormonal deficiency.
20. Walsh, C. T., Garneau-Tsodikova, S. & Gatto, G. J. Jr. Protein posttranslational modifications: the chemistry of proteome
21. Strom, B. O. & Paulsen, R. E. Apoptosis inducer NGFI-B is degraded by the proteasome and stabilized by treatment with EGF.
22. Litchfield, D. W. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death.
23. Meggio, F. & Pinna, L. A. One-thousand-and-one substrates of protein kinase CK2?
24. Cavin, L. G.
40. Zhan, Y.
6. Pei, L., Castrillo, A., Chen, M., Hoffmann, A. & Tontonoz, P. Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli.
32. Lix, B. A., Lin, H. & Cai, Y. Endogenous pin1 is required for antigenic drug cisplatin-induced apoptosis.
30. Zou, W., Zhang, B., Liu, J., Guan, K. L. & Jiang, Y. Protein kinase CK2: A new regulator of the Notch signaling pathway.
31. Marsaux, F., Berthet, A. P., Guegan, A., Gonthier, J. L. & Tsubouchi, J. H. Phosphorylation of the orphan nuclear receptor TR3 by Pin1.
32. Zhang, J. et al. Impeding the interaction between Nur77 and p38 reduces LPS-induced inflammation. Nat Chem Biol 11, 339–346, https://doi.org/10.1038/nchembio.1788 (2015).
33. Rajsbaum, R., Garcia-Sastre, A. & Versteeg, G. A. TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral
34. Lerner, M.
35. Lerner, M. et al. Nuclear receptor 4A (NR4A) family - orphans no more. J Steroid Biochem Mol Biol 157, 48–60, https://doi.org/10.1016/j.jsbmb.2015.04.016 (2016).
36. Pei, L., Castrillo, A., Chen, M., Hoffmann, A. & Tontonoz, P. Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli.
37. Rodriguez-Calvo, R., Tajes, M. & Vazquez-Carrera, M. The NR4A subfamily of nuclear receptors: potential new therapeutic targets
38. Wansa, K. D., Harris, J. M. & Muscat, G. E. The activation function-1 domain of Nur77/NR4A1 mediates trans-activation, cell
39. Zhan, Y. Y.
45. Hamers, A. A. et al. Bone marrow-specific deficiency of nuclear receptor Nur77 enhances atherosclerosis. *Circ Res* **110**, 428–438, https://doi.org/10.1161/CIRCRESAHA.111.260760 (2012).
46. Yang, P. et al. Antithrombotic Effects of Nur77 and Nor1 Are Mediated Through Upregulating Thrombomodulin Expression in Endothelial Cells. *Arterioscler Thromb Vasc Biol* **36**, 361–369, https://doi.org/10.1161/ATVBAHA.115.306891 (2016).
47. Hamers, A. A. et al. Deficiency of Nuclear Receptor Nur77 Aggravates Mouse Experimental Colitis by Increased NFkappaB Activity in Macrophages. *PLoS One* **10**, e0133598, https://doi.org/10.1371/journal.pone.0133598 (2015).

**Acknowledgements**

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2015R1D1A3A01015809 to S.H.B) and NRF grant funded by the Korea government (MSIP) (NRF-2015R1A2A2A05001024 to H.W.C).

**Author Contributions**

H.-W.C. and S.-H.B. participated, designed, and supervised. B.H. and H.Z.P. conducted experiments. S.-H.B. wrote the manuscript and H.-W.C. and B.H. contributed to the writing of the manuscript. All authors discussed the results and commented on the manuscript.

**Additional Information**

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-32391-5.

**Competing Interests:** The authors declare no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2018